Pre-market most active: MOREPENLAB.NS Morepen Labs (NSE) INR 46.47, vol 84.44M watch breakout

MOREPENLAB.NS stock is the top pre-market mover on the NSE after trading at INR 46.47 with a volume of 84.44M shares. The stock opened at INR 45.51 and already shows a day range between INR 45.28 and INR 48.84. Traders are watching the 50-day average of INR 38.66 and the 200-day average of INR 49.75 for directional cues. This pre-market activity raises the chance of strong intraday swings for Morepen Laboratories Limited on the India market.

MOREPENLAB.NS stock: Pre-market snapshot

Morepen Laboratories Limited (MOREPENLAB.NS) trades on the NSE in India at INR 46.47 with 84.44M shares pre-market. Volume is large versus an average daily volume of 1.68M, giving a relative volume of 8.08 and higher intraday volatility probability.

Price opened at INR 45.51 and the session high is INR 48.84. Immediate support sits near INR 45.28 and near-term resistance at INR 48.84.

Technical view and trading cues

Technicals show momentum but some overbought signals. RSI is 62.95, MACD histogram is 0.87, and Money Flow Index is 91.11, indicating buying pressure.

Bollinger band middle is INR 39.20 with upper at INR 44.97. The 50-day average is INR 38.66 and the 200-day average is INR 49.75. For active traders, a close above INR 49.75 would confirm strength. Use a stop-loss near INR 45.00 for short-term trades.

Fundamental snapshot and valuation

Morepen Laboratories Limited shows a market cap of INR 24,208,594,422.00, EPS of INR 1.80, and a P/E ratio of 24.54. Price-to-book is 2.03 and return on equity is 8.55%, indicating moderate profitability versus sector peers.

Current ratio is 2.23, and net debt metrics are low, with debt-to-equity near 0.13. The company pays a small dividend of INR 0.20 per share and operates in the Healthcare sector across APIs and home-health devices.

Meyka AI grade and model forecast

Meyka AI rates MOREPENLAB.NS with a score out of 100: 75.04 | Grade: B+ | Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Meyka AI’s forecast model projects a yearly price of INR 61.30, versus the current INR 46.47, implying an upside of 31.89%. The model’s monthly figure is INR 41.39, which implies a short-term downside of -10.93%. Forecasts are model-based projections and not guarantees.

Catalysts, earnings and risks

Key catalyst is the next earnings announcement on 2026-05-11, which may add fresh directional signals. Sector momentum in Healthcare remains mixed; the sector average P/E is 39.51, while Morepen’s P/E is 24.54, suggesting a relative valuation discount.

Risks include thin free cash flow reporting in recent metrics, a third-party company rating of D+ dated 2026-02-25, and heightened volatility from large pre-market volume. Monitor receivables and inventory days, currently 55.83 and 86.24 days respectively.

Trading strategy for most active pre-market traders

For the most active traders, focus on volume, VWAP, and the INR 45.00 support level. A breakout trade above INR 49.75 with sustained volume can target INR 55.00 initially and INR 61.30 on strong follow-through.

Use tight risk control and scale positions. Given the pre-market relative volume of 8.08, expect sharper moves and wider stops than average. Check order flow and confirm with NSE liquidity before entry.

Final Thoughts

MOREPENLAB.NS stock leads pre-market activity on the NSE with INR 46.47 and an outsized volume of 84.44M shares. Technicals show momentum, yet indicators like MFI at 91.11 warn of near-term overbought conditions. Fundamentally, the company trades at a P/E of 24.54 and a PB of 2.03, below Healthcare sector multiples. Meyka AI rates MOREPENLAB.NS 75.04/100 (Grade B+, Suggestion: BUY) and its forecast model projects INR 61.30 in one year, implying 31.89% upside versus the current price. Short-term traders should respect the monthly model of INR 41.39, which implies a potential pullback. Remember these grades and forecasts are model-based and not guarantees. Use position sizing and stop-losses, and watch the earnings date on 2026-05-11 for a potential directional catalyst. Meyka AI provides this AI-powered market analysis as context, not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.